Retatrutide vs. Semaglutide vs. Tirzepatide: The Ultimate GLP-1 Showdown

If you have been paying attention to the weight loss space over the last few years, you have probably heard the names Ozempic, Mounjaro, and Wegovy thrown around constantly. But now there is a new name entering the conversation: retatrutide. And the data behind it is genuinely jaw-dropping.

So what actually separates these three drugs? Are they all just "GLP-1 shots"? Which one is right for you? And should you wait for retatrutide or start now? Let's walk through all of it together — no jargon, no hype, just the real science.

First, What Are These Drugs Actually Doing?

All three drugs work by mimicking hormones your gut naturally produces after you eat. These hormones signal your brain to feel full, slow down how fast your stomach empties, and help regulate blood sugar. The key difference between the three is how many of these hormonal pathways they activate.

Think of it like a lock-and-key system. Your metabolism has three important locks: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Each drug carries a different set of keys.

More receptors activated means more metabolic levers being pulled at the same time. That is why the weight loss numbers keep climbing with each generation. But it also means the side effect profile gets more complex. Let's look at each one in detail.

Semaglutide: The One That Started It All

Semaglutide (sold as Ozempic for type 2 diabetes and Wegovy for obesity) was the drug that made the world pay attention. It is a single GLP-1 receptor agonist, meaning it mimics the GLP-1 hormone that your intestines release after a meal. That signal tells your brain you are full, slows gastric emptying, and helps stabilize blood sugar.

In the landmark STEP 1 clinical trial, participants taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks. The STEP 5 trial extended this out to two years and showed the results held: 15.2% sustained weight loss at 104 weeks. These were numbers the medical community had never seen from a non-surgical weight loss intervention.

The cardiovascular data is also impressive. The SELECT trial, published in the New England Journal of Medicine in 2023, showed semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity and established heart disease. This is the strongest cardiovascular outcome data of any drug in this class.

Semaglutide is also the only drug in this group available in an oral pill form (Rybelsus), which is a meaningful advantage for people who are needle-averse.

The most common side effects are gastrointestinal: nausea affects about 44% of users, diarrhea about 30%, and vomiting about 24%. These tend to be worst in the first few weeks and improve as the body adjusts. The standard approach is to start at a low dose and titrate up slowly over several months.

Tirzepatide: The Dual Agonist That Raised the Bar

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) added a second key to the lock. It activates both the GLP-1 receptor and the GIP receptor simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone that enhances insulin secretion and, interestingly, may also play a direct role in fat storage and energy balance.

The SURMOUNT-1 trial was the headline moment for tirzepatide. At the highest dose of 15 mg weekly, participants lost an average of 22.5% of their body weight over 72 weeks. At 5 mg it was 15%, and at 10 mg it was 21.4%. The SURMOUNT-4 trial, which looked at what happens when you keep taking it, showed 25.3% weight loss at 88 weeks with continued treatment.

A real-world head-to-head comparison published in JAMA Internal Medicine in 2024 confirmed what the trials suggested: patients on tirzepatide consistently lost more weight than those on semaglutide at 3, 6, and 12 months. This is not a small difference — it is clinically meaningful.

Side effects are similar to semaglutide but slightly more pronounced at higher doses. Nausea ranges from 31–45% depending on dose, diarrhea from 17–30%, and vomiting from 8–22%. The slower titration schedule (starting at 2.5 mg) helps most people manage these effects.

Tirzepatide is currently the most effective FDA-approved weight loss medication available. If you want the best results you can get right now, this is the current gold standard.

Retatrutide: The Triple Agonist That Could Change Everything

Retatrutide is where things get genuinely exciting. Developed by Eli Lilly, it is the world's first triple hormone receptor agonist — activating GLP-1, GIP, and glucagon receptors simultaneously. Adding the glucagon receptor is the key innovation. Glucagon normally raises blood sugar, but when its receptor is activated in the context of GLP-1 and GIP signaling, it dramatically increases energy expenditure and fat burning. The three pathways working together create a metabolic effect that is greater than the sum of its parts.

The phase 2 data, published in the New England Journal of Medicine in 2023, showed 24.2% weight loss at 48 weeks with the 12 mg dose. Then in December 2025, Eli Lilly announced the results of the phase 3 TRIUMPH-4 trial — and the numbers were unprecedented.

Over 68 weeks, participants taking 12 mg of retatrutide lost an average of 28.7% of their body weight — that is an average of 71.2 pounds. The 9 mg dose produced 26.4% weight loss. The placebo group lost just 2.1%. To put that in context: the average participant started at 248 pounds with a BMI of 40, and ended up losing more than a quarter of their body weight without surgery.

The secondary endpoints were equally striking. 58% of participants on the 12 mg dose achieved at least 25% weight loss. Nearly 24% achieved 35% or more. One in eight participants reported complete resolution of knee pain from osteoarthritis — a finding that suggests retatrutide's benefits extend well beyond the scale.

The side effect profile for retatrutide is similar to the other two drugs. Nausea affected 38–43% of participants, and treatment discontinuation occurred in 12–18% of the retatrutide groups compared to 4% in the placebo group. Seven additional phase 3 trials are currently underway evaluating retatrutide in obesity and type 2 diabetes, with results expected throughout 2026.

Important note: Retatrutide is not yet FDA approved. An NDA (New Drug Application) is expected in Q4 2026, with approval projected for late 2027 at the earliest. It is currently only available through clinical trials.

So Which One Is Right for You?

Here is the honest answer: it depends on where you are starting from and what matters most to you right now.

Choose semaglutide if you want the most proven, longest-track-record option. It has the strongest cardiovascular outcome data of any drug in this class (the SELECT trial), it is available in oral form, and it has been in widespread use since 2021. If you have established heart disease and obesity, this is the one your cardiologist is most likely to recommend. It is also the most widely available and the most studied for long-term effects.

Choose tirzepatide if you want the best results currently available from an FDA-approved drug. The dual GIP/GLP-1 mechanism consistently outperforms semaglutide in head-to-head comparisons, and the SURMOUNT trial data is robust. It is especially effective for people with type 2 diabetes or significant insulin resistance, where the GIP pathway may play a larger role.

Watch retatrutide if you are dealing with severe obesity (BMI 40+), have not gotten the results you hoped for from tirzepatide, or are interested in the additional benefits beyond weight loss — particularly for metabolic liver disease (MASLD/NASH) or osteoarthritis. The phase 3 data is extraordinary, but you will need to wait for FDA approval unless you qualify for a clinical trial.

The Bigger Picture

What is remarkable about this progression — from semaglutide to tirzepatide to retatrutide — is how quickly the field is moving. Each generation has roughly doubled the weight loss outcomes of the previous one. That trajectory is almost without precedent in pharmacology.

It is also worth remembering that these drugs work best as part of a comprehensive approach. The clinical trials all included lifestyle counseling alongside the medication. The people who see the best results are the ones who use the drug as a tool to build better habits — not as a substitute for them. Nutrition, sleep, and movement still matter enormously.

If you want to dive deeper into the science behind GLP-1 peptides, check out our full library profiles on Semaglutide, Tirzepatide, and Retatrutide — or explore our Retatrutide vs. Tirzepatide comparison page for a deeper side-by-side breakdown.

References

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021. PubMed
2. Ryan DH, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." New England Journal of Medicine, 2023. PubMed
3. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022. PubMed
4. Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." New England Journal of Medicine, 2023. PubMed
5. Eli Lilly. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs." TRIUMPH-4 Phase 3 Press Release, December 11, 2025.
6. Salhab A, et al. "Comparative Efficacy and Safety of Tirzepatide vs Retatrutide." PMC, 2025. PMC